Atopic Dermatitis (AD) is a chronic inflammatory skin condition that affects an estimated 220 million people worldwide. Current mainstay treatments often rely on steroids and other immunosuppressants, which can cause significant side effects, or antibiotics, which contribute to antimicrobial resistance.
Antenovus Biotechnology is pioneering a new approach with a first-in-class, non-steroidal, non-immunosuppressant, non-antibiotic topical drug. The company's treatment is specifically designed to inhibit the virulence mechanisms of Staphylococcus aureus - a key pathogen identified by scientists as a crucial driver of the debilitating itch and inflammation in AD. By precisely targeting this root cause, the team aims to provide lasting relief and significantly improve the quality of life for patients.
Prof. Richard KAO
Associate Professor
Department of Microbiology
LKS Faculty of Medicine
Email: rytkao@hku.hk
Awardee of the 2017 Hubert Tidy Prize - International Consortium on Prevention and Infection Control (ICPIC) Innovation Academy Award at Geneva, Switzerland
